Developer docs
API playgroundTry for free, no card

Search company profiles

RespiQ

Full company profile

uuid0002qmp

Namestring
RespiQ
Legal namestring
Respiro B.V.
Websiteurl
respiq.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

RespiQ (legal entity: Respiro B.V.) is a Dutch deep-tech health startup founded in 2019 and headquartered in Amsterdam that builds a hardware-and-software breath diagnostics platform. Its core technology combines plasma emission spectroscopy with proprietary machine-learning pipelines to detect volatile organic compounds (VOCs) in exhaled breath at parts-per-billion sensitivity, versus the parts-per-million benchmark of conventional breath-analysis approaches. The platform is designed for point-of-care and, eventually, at-home use, with an interpretable-AI architecture that traces every prediction back to scientifically meaningful molecular features — a deliberate choice to support clinical adoption and regulatory clearance under EU MDR/IVDR.

The product surface is structured around a single hardware-as-a-service device that powers multiple health applications via software updates. Two applications — COPD health monitoring (remote breath biomarker tracking for early detection of exacerbations) and a Gut Health module for food intolerance, SIBO, and IBS — entered clinical trials in 2024, while SIBO and Asthma are slated for R&D in 2026 and Lung Cancer for R&D in 2027. RespiQ is pre-commercial; its commercial go-to-market is currently enterprise field sales to clinics and HCPs (pulmonologists, dieticians, nutritionists, GPs), with a planned direct-to-consumer motion. Pricing is undisclosed but operates on a subscription hardware-as-a-service model.

The company is primarily grant-funded, anchored by a €4 million EIC Pathfinder Challenge Grant (Nov 2023) alongside a €105k Antler pre-seed (2019) and additional non-dilutive support from DIGI-B-CUBE, RVO's VFF, Rabobank Innovation Loan, Eurostars, BiotechBooster, and Women TechEU. It operates within a deep research and translational consortium network that includes Amsterdam UMC, LUMC, King's College London, SINTEF, and uRoboptics, and participated in the EIC Multi-Corporate Day (Oct 2025) engaging P&G, Air Liquide, Chiesi, Merck, and Nestlé. Leadership comprises CEO Ernst Breel, Founder/CFO-CSO Mira Gleisberg (formerly CEO), CTO/co-founder Vitalii Vorkov, and a PhD-heavy technical team.

Short descriptiontext

RespiQ is a Dutch deep-tech health startup building a hardware-as-a-service breath diagnostics platform that uses plasma emission spectroscopy and AI to detect VOC biomarkers at parts-per-billion sensitivity, initially targeting COPD and gut-health applications for clinicians and, eventually, consumers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLeiden, Netherlands
HQ citystring
Leiden
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
breath diagnostics, VOC biomarker analysis, respiratory health monitoring, gut health diagnostics, non-invasive medical devices
Industry1 code
PRIMARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Breath Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Hardware-as-a-Service (Device as a Service)
TypeSubscription Recurring
Description

The company offers its breath analysis device as a service (hardware-as-a-service). This model provides customers with the ability to collect data and expand into new health domains via software updates. The subscription-style recurring revenue model enables continuous value delivery.

respiq.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Device as a Service subscription model
ModelSubscriptionBilling cadenceNot specified
Notes

Device offered as a service with software update capabilities for expanding into new health domains. Specific pricing tiers not publicly disclosed.

respiq.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

RespiQ develops a compact breath analysis device that combines plasma emission spectroscopy with AI and machine learning to detect volatile organic compounds (VOCs) in human breath at parts-per-billion sensitivity. The device enables non-invasive, real-time detection of disease-related biomarkers for early diagnosis and chronic disease management, with initial focus on COPD/respiratory health and gut health conditions (food intolerance, SIBO, IBS). The hardware is offered via a hardware-as-a-service subscription model that allows customers to expand into new health domains through software updates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Detection sensitivity improved from parts-per-million to parts-per-billion levels
+4 more records
Product overview1 text field

RespiQ offers a breath diagnostics platform consisting of a hardware device and software analysis system. The core product is a compact breath analysis device (hardware-as-a-service model) that detects volatile organic compounds at parts-per-billion sensitivity. The platform powers multiple health applications: COPD Health Monitoring for respiratory care, and Gut Health/GutSense for digestive health management (food intolerance, SIBO, IBS). The device is initially available to health professionals, with plans to expand to patients and consumers. Software updates enable expansion into new health domains.

Product and service1 record
1RespiQ Breath Analysis Device
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-24
Description

Consortium partner in the €4M EIC Pathfinder Challenge Grant for developing breath diagnostics technology for COPD patient monitoring. LUMC (Leiden University Medical Center) conducts clinical trials for COPD.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-24
Description

Consortium partner in the €4M EIC Pathfinder Challenge Grant alongside Nell-LUMC, Kings College London, and uRoboptics for breath diagnostics technology development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-24
Description

Consortium partner in the €4M EIC Pathfinder Challenge Grant for breath diagnostics technology for COPD patient monitoring. Contributes academic research expertise to the project.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-24
Description

Consortium partner in the €4M EIC Pathfinder Challenge Grant and the Eurostars COPDetect project with Amsterdam UMC. Works on improving and automating RespiQ sensor technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-04
Description

Partner in Eurostars COPDetect project for developing breath-based COPD detection technology. Amsterdam UMC leads a team of over 40 researchers at the department of pulmonary disease focusing on precision medicine.

6P4O2 (Precision Medicine for more Oxygen) Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-02-26
Description

Dutch research consortium coordinated by Amsterdam UMC with a budget of over €14.5 million, co-funded by Health~Holland. RespiQ participates in research focusing on lifestyle intervention and personalized nutrition for improving early detection, prevention, and treatment of lung diseases including asthma, COPD, and lung cancer.

respiq.com
7Food Valley
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner organization, likely related to food intolerance and gut health research initiatives.

respiq.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner organization, contributing to the ecosystem of research and development partners.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Awarded Biotech Booster grant for GutSense project. BiotechBooster supports innovative biotech ventures in the Netherlands.

Strategic tierMinorTypeGTM or Marketing Partner
Description

RespiQ won Women TechEU support program, providing visibility and ecosystem support for women-led tech startups in Europe.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based leader in breath biopsy for early disease detection, developing VOC-based diagnostics for cancer, inflammatory, and infectious diseases. Directly comparable to RespiQ as a peer in clinical-stage breath diagnostics targeting multiple indications with a hardware-plus-software platform.

TypeDirect peer
Description

Dutch breath analysis company developing eNose-based technology for respiratory and metabolic disease diagnostics. Directly comparable to RespiQ as a Netherlands-headquartered breath diagnostics peer targeting similar clinical applications.

TypeDirect peer
Description

Canada-based breath diagnostics company developing VOC-based disease detection for respiratory and metabolic conditions. Directly comparable as a startup competitor in AI-powered breath biomarker analysis.

TypeDirect peer
Description

UK-based manufacturer of breath analysis medical devices including Smokerlyzer, GastroCH4ECK, and NObreath FeNO monitors. Comparable as a commercial-stage breath diagnostics device maker targeting respiratory and gut health applications.

TypeBroad incumbent
Description

Commercial-stage respiratory diagnostics company focused on fractional exhaled nitric oxide (FeNO) testing for asthma. Comparable as a regulatory-cleared breath-based respiratory diagnostic device maker operating in an overlapping clinical use case.

6Aer Nosor
TypeEmerging player
Description

Emerging breath diagnostics company developing electronic nose technology for lung disease and cancer screening. Comparable as an early-stage competitor in VOC-based breath diagnostics with overlapping target indications.

TypeEmerging player
Description

US-based respiratory health technology company developing wearable pulmonary monitoring and AI-enabled lung sound analysis. Comparable as a respiratory digital health startup focused on remote patient monitoring for chronic lung disease.

8Cambridge Respiratory Innovations (CRiL)
TypeEmerging player
Description

UK-based developer of the N-Tidal device for real-time capnography-based respiratory monitoring. Comparable as a breath diagnostics hardware-and-software platform targeting chronic respiratory disease management.

TypeBroad incumbent
Description

Global medtech incumbent with respiratory care, sleep, and patient monitoring portfolios. RespiQ's founder Mira Gleisberg previously worked at Philips, and the company competes for clinical mindshare in respiratory diagnostics against Philips' broader portfolio.

TypeRegional player
Description

Netherlands-based developer of electronic nose technology for detecting diseases through exhaled breath. Comparable as a Dutch peer in breath-based disease diagnostics with overlapping target indications in respiratory and infectious disease.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RespiQ

Breath Diagnosticsrespiq.com

RespiQ is a Dutch deep-tech health startup building a hardware-as-a-service breath diagnostics platform that uses plasma emission spectroscopy and AI to detect VOC biomarkers at parts-per-billion sensitivity, initially targeting COPD and gut-health applications for clinicians and, eventually, consumers.

What RespiQ does

RespiQ (legal entity: Respiro B.V.) is a Dutch deep-tech health startup founded in 2019 and headquartered in Amsterdam that builds a hardware-and-software breath diagnostics platform. Its core technology combines plasma emission spectroscopy with proprietary machine-learning pipelines to detect volatile organic compounds (VOCs) in exhaled breath at parts-per-billion sensitivity, versus the parts-per-million benchmark of conventional breath-analysis approaches. The platform is designed for point-of-care and, eventually, at-home use, with an interpretable-AI architecture that traces every prediction back to scientifically meaningful molecular features — a deliberate choice to support clinical adoption and regulatory clearance under EU MDR/IVDR.

The product surface is structured around a single hardware-as-a-service device that powers multiple health applications via software updates. Two applications — COPD health monitoring (remote breath biomarker tracking for early detection of exacerbations) and a Gut Health module for food intolerance, SIBO, and IBS — entered clinical trials in 2024, while SIBO and Asthma are slated for R&D in 2026 and Lung Cancer for R&D in 2027. RespiQ is pre-commercial; its commercial go-to-market is currently enterprise field sales to clinics and HCPs (pulmonologists, dieticians, nutritionists, GPs), with a planned direct-to-consumer motion. Pricing is undisclosed but operates on a subscription hardware-as-a-service model.

The company is primarily grant-funded, anchored by a €4 million EIC Pathfinder Challenge Grant (Nov 2023) alongside a €105k Antler pre-seed (2019) and additional non-dilutive support from DIGI-B-CUBE, RVO's VFF, Rabobank Innovation Loan, Eurostars, BiotechBooster, and Women TechEU. It operates within a deep research and translational consortium network that includes Amsterdam UMC, LUMC, King's College London, SINTEF, and uRoboptics, and participated in the EIC Multi-Corporate Day (Oct 2025) engaging P&G, Air Liquide, Chiesi, Merck, and Nestlé. Leadership comprises CEO Ernst Breel, Founder/CFO-CSO Mira Gleisberg (formerly CEO), CTO/co-founder Vitalii Vorkov, and a PhD-heavy technical team.

RespiQ firmographics

Firmographics
Name
RespiQ
Legal name
Respiro B.V.
Website
https://respiq.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
RespiQ is a Dutch deep-tech health startup building a hardware-as-a-service breath diagnostics platform that uses plasma emission spectroscopy and AI to detect VOC biomarkers at parts-per-billion sensitivity, initially targeting COPD and gut-health applications for clinicians and, eventually, consumers.
Ownership category
akta.pro rank

RespiQ industry classification

Industry
Product category
Breath Diagnostics
NAICS
Medical Laboratories (621511)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Breath diagnostics
  • VOC biomarker analysis
  • Respiratory health monitoring
  • Gut health diagnostics
  • Non-invasive medical devices

Where RespiQ is headquartered

Location

Headquarters

HQ city
Leiden
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

RespiQ business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Hardware-as-a-Service (Device as a Service): The company offers its breath analysis device as a service (hardware-as-a-service). This model provides customers with the ability to collect data and expand into new health domains via software updates. The subscription-style recurring revenue model enables continuous value delivery.

Pricing tiers

ModelBillingPrice
SubscriptionNot specifiedDevice as a Service subscription model

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

RespiQ product offering

Product offering

Core offering

RespiQ develops a compact breath analysis device that combines plasma emission spectroscopy with AI and machine learning to detect volatile organic compounds (VOCs) in human breath at parts-per-billion sensitivity. The device enables non-invasive, real-time detection of disease-related biomarkers for early diagnosis and chronic disease management, with initial focus on COPD/respiratory health and gut health conditions (food intolerance, SIBO, IBS). The hardware is offered via a hardware-as-a-service subscription model that allows customers to expand into new health domains through software updates.

Product overview

RespiQ offers a breath diagnostics platform consisting of a hardware device and software analysis system. The core product is a compact breath analysis device (hardware-as-a-service model) that detects volatile organic compounds at parts-per-billion sensitivity. The platform powers multiple health applications: COPD Health Monitoring for respiratory care, and Gut Health/GutSense for digestive health management (food intolerance, SIBO, IBS). The device is initially available to health professionals, with plans to expand to patients and consumers. Software updates enable expansion into new health domains.

Differentiator

Problem solved

Functional benefit

Products and services

  • RespiQ Breath Analysis Device

Quantifiable outcome

  • Detection sensitivity improved from parts-per-million to parts-per-billion levels
  • +4 more outcomes

Companies that use RespiQ

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles1 record

RespiQ technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

RespiQ partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • Nell-LUMCcoreStrategic or Co-development Partner · 24 November 2023Consortium partner in the €4M EIC Pathfinder Challenge Grant for developing breath diagnostics technology for COPD patient monitoring. LUMC (Leiden University Medical Center) conducts clinical trials for COPD.
  • SintefcoreStrategic or Co-development Partner · 24 November 2023Consortium partner in the €4M EIC Pathfinder Challenge Grant alongside Nell-LUMC, Kings College London, and uRoboptics for breath diagnostics technology development.
  • Kings College LondoncoreStrategic or Co-development Partner · 24 November 2023Consortium partner in the €4M EIC Pathfinder Challenge Grant for breath diagnostics technology for COPD patient monitoring. Contributes academic research expertise to the project.
  • uRobopticscoreStrategic or Co-development Partner · 24 November 2023Consortium partner in the €4M EIC Pathfinder Challenge Grant and the Eurostars COPDetect project with Amsterdam UMC. Works on improving and automating RespiQ sensor technology.
  • Amsterdam UMCcoreStrategic or Co-development Partner · 4 July 2023Partner in Eurostars COPDetect project for developing breath-based COPD detection technology. Amsterdam UMC leads a team of over 40 researchers at the department of pulmonary disease focusing on precision medicine.
  • P4O2 (Precision Medicine for more Oxygen) ConsortiumcoreStrategic or Co-development Partner · 26 February 2021Dutch research consortium coordinated by Amsterdam UMC with a budget of over €14.5 million, co-funded by Health~Holland. RespiQ participates in research focusing on lifestyle intervention and personalized nutrition for improving early detection, prevention, and treatment of lung diseases including asthma, COPD, and lung cancer.
  • Food ValleyminorStrategic or Co-development PartnerListed as a partner organization, likely related to food intolerance and gut health research initiatives.
  • De Haagse HogeschoolminorStrategic or Co-development PartnerListed as a partner organization, contributing to the ecosystem of research and development partners.
  • BiotechBoosterminorStrategic or Co-development PartnerAwarded Biotech Booster grant for GutSense project. BiotechBooster supports innovative biotech ventures in the Netherlands.
  • Women TechEUminorGTM or Marketing PartnerRespiQ won Women TechEU support program, providing visibility and ecosystem support for women-led tech startups in Europe.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

RespiQ competitors and assessment

Company assessment

Direct peers

  • Owlstone Medical: UK-based leader in breath biopsy for early disease detection, developing VOC-based diagnostics for cancer, inflammatory, and infectious diseases. Directly comparable to RespiQ as a peer in clinical-stage breath diagnostics targeting multiple indications with a hardware-plus-software platform.
  • Breathomix: Dutch breath analysis company developing eNose-based technology for respiratory and metabolic disease diagnostics. Directly comparable to RespiQ as a Netherlands-headquartered breath diagnostics peer targeting similar clinical applications.
  • Noze: Canada-based breath diagnostics company developing VOC-based disease detection for respiratory and metabolic conditions. Directly comparable as a startup competitor in AI-powered breath biomarker analysis.
  • Bedfont Scientific: UK-based manufacturer of breath analysis medical devices including Smokerlyzer, GastroCH4ECK, and NObreath FeNO monitors. Comparable as a commercial-stage breath diagnostics device maker targeting respiratory and gut health applications.

Broad incumbents

  • Spirosure (Circassia): Commercial-stage respiratory diagnostics company focused on fractional exhaled nitric oxide (FeNO) testing for asthma. Comparable as a regulatory-cleared breath-based respiratory diagnostic device maker operating in an overlapping clinical use case.
  • Philips: Global medtech incumbent with respiratory care, sleep, and patient monitoring portfolios. RespiQ's founder Mira Gleisberg previously worked at Philips, and the company competes for clinical mindshare in respiratory diagnostics against Philips' broader portfolio.

Emerging players

  • Aer Nosor: Emerging breath diagnostics company developing electronic nose technology for lung disease and cancer screening. Comparable as an early-stage competitor in VOC-based breath diagnostics with overlapping target indications.
  • Strados Labs: US-based respiratory health technology company developing wearable pulmonary monitoring and AI-enabled lung sound analysis. Comparable as a respiratory digital health startup focused on remote patient monitoring for chronic lung disease.
  • Cambridge Respiratory Innovations (CRiL): UK-based developer of the N-Tidal device for real-time capnography-based respiratory monitoring. Comparable as a breath diagnostics hardware-and-software platform targeting chronic respiratory disease management.

Regional players

  • eNose Company: Netherlands-based developer of electronic nose technology for detecting diseases through exhaled breath. Comparable as a Dutch peer in breath-based disease diagnostics with overlapping target indications in respiratory and infectious disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

RespiQ social profiles

Digital presence

RespiQ financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RespiQ leadership team

Management profile

Number of profiles

Profiles9 records

RespiQ funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RespiQ M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RespiQ

What does RespiQ do?

RespiQ develops a compact breath analysis device that combines plasma emission spectroscopy with AI and machine learning to detect volatile organic compounds (VOCs) in human breath at parts-per-billion sensitivity. The device enables non-invasive, real-time detection of disease-related biomarkers for early diagnosis and chronic disease management, with initial focus on COPD/respiratory health and gut health conditions (food intolerance, SIBO, IBS). The hardware is offered via a hardware-as-a-service subscription model that allows customers to expand into new health domains through software updates.

Is RespiQ a public or private company?

RespiQ is a private company. It is classified as venture growth investor backed and is currently operating.

When was RespiQ founded?

RespiQ was founded in 2019. It employs 11 to 50 people.

Where is RespiQ based?

RespiQ is headquartered in Leiden, Netherlands, in the Europe region.

How does RespiQ make money?

One revenue line is on record: hardware-as-a-Service (Device as a Service).

Who are RespiQ's main competitors?

Direct peers on record are Owlstone Medical, Breathomix, Noze and Bedfont Scientific. Broad incumbents are Spirosure (Circassia) and Philips. Emerging players are Aer Nosor, Strados Labs and Cambridge Respiratory Innovations (CRiL). eNose Company is listed as a regional player.

Does RespiQ have an API?

No public API is recorded for RespiQ.

What industry is RespiQ in?

RespiQ's product category is Breath Diagnostics. Its primary akta.pro industry code is HLAHACAD, Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry). Its NAICS code is 621511 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals